50 related articles for article (PubMed ID: 9886326)
1. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.
Schröder JK; Kirch C; Seeber S; Schütte J
Br J Haematol; 1998 Dec; 103(4):1096-103. PubMed ID: 9886326
[TBL] [Abstract][Full Text] [Related]
2. Correction to "Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients".
Br J Haematol; 2024 May; 204(5):2136. PubMed ID: 38529802
[No Abstract] [Full Text] [Related]
3. 8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment.
Wu PS; Wang CY; Hsu HJ; Yen JH; Wu MJ
Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002257
[TBL] [Abstract][Full Text] [Related]
4. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report.
Sheel A; Bae J; Asada A; Otterson GA; Baliga RR; Koenig KL
Cardiooncology; 2023 Jan; 9(1):4. PubMed ID: 36653885
[TBL] [Abstract][Full Text] [Related]
5. Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á; Labrador J; Zubiaur P; Alcaraz R; Herrero MJ; Montesinos P; Abad-Santos F; Saiz-Rodríguez M
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335935
[TBL] [Abstract][Full Text] [Related]
6. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.
Di Francia R; Crisci S; De Monaco A; Cafiero C; Re A; Iaccarino G; De Filippi R; Frigeri F; Corazzelli G; Micera A; Pinto A
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669053
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
[TBL] [Abstract][Full Text] [Related]
8. The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?
Frances A; Cordelier P
Mol Ther; 2020 Feb; 28(2):357-366. PubMed ID: 31870623
[TBL] [Abstract][Full Text] [Related]
9. Novel L-nucleoside analogue, 5-fluorotroxacitabine, displays potent efficacy against acute myeloid leukemia.
Bankar A; Siriwardena TP; Rizoska B; Rydergård C; Kylefjord H; Rraklli V; Eneroth A; Pinho P; Norin S; Bylund J; Moses S; Bethell R; Kavanagh S; Maclean N; Gronda M; Wang X; Hurren R; Minden MD; Targett-Adams P; Schimmer AD; Albertella M
Haematologica; 2021 Feb; 106(2):574-579. PubMed ID: 31857370
[No Abstract] [Full Text] [Related]
10. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
11. Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
Sankhala K; Takimoto CH; Mita AC; Xiong H; Rodón J; Mehrvarz Sarshekeh A; Burns K; Iizuka K; Kopetz S
Invest New Drugs; 2019 Feb; 37(1):76-86. PubMed ID: 29667134
[TBL] [Abstract][Full Text] [Related]
12. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
[TBL] [Abstract][Full Text] [Related]
13. Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells.
Ruan H; Qiu S; Beard BC; Black ME
Protein Eng Des Sel; 2016 Dec; 29(12):573-582. PubMed ID: 27160178
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Ciccolini J; Serdjebi C; Peters GJ; Giovannetti E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):1-12. PubMed ID: 27007129
[TBL] [Abstract][Full Text] [Related]
15. Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
Medina-Sanson A; Ramírez-Pacheco A; Moreno-Guerrero SS; Dorantes-Acosta EM; Sánchez-Preza M; Reyes-López A
Biomed Res Int; 2015; 2015():309491. PubMed ID: 26090398
[TBL] [Abstract][Full Text] [Related]
16. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Gamazon ER; Lamba JK; Pounds S; Stark AL; Wheeler HE; Cao X; Im HK; Mitra AK; Rubnitz JE; Ribeiro RC; Raimondi S; Campana D; Crews KR; Wong SS; Welsh M; Hulur I; Gorsic L; Hartford CM; Zhang W; Cox NJ; Dolan ME
Blood; 2013 May; 121(21):4366-76. PubMed ID: 23538338
[TBL] [Abstract][Full Text] [Related]
18. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Emadi A; Karp JE
Pharmacogenomics; 2012 Aug; 13(11):1257-69. PubMed ID: 22920396
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
20. Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents.
Crespan E; Garbelli A; Amoroso A; Maga G
Molecules; 2011 Sep; 16(9):7994-8019. PubMed ID: 21926946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
